Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01979601 · ClinicalTrials.gov registry record · Phase 1
Safety, Tolerability, PK and PD of LGT209 in Healthy Volunteers and Patients With Hypercholesterolemia
A Phase 1 study of Hypercholesterolemia, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 74
- Enrollment target
- 2
- Study locations
NCT01979601: Completed Phase 1 study of Hypercholesterolemia, sponsored by Novartis Pharmaceuticals.
NCT01979601 is a Phase 1 study of Hypercholesterolemia that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 74 participants, below the 816-participant average among 62 other Hypercholesterolemia trials with a reported enrollment target (91% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01979601, a Phase 1 study of Hypercholesterolemia, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 74 participants
- Enrollment target
- 2
- Study locations
Study Summary
This study is designed to measure the effects of LGT209 when given intravenously to patients with high cholesterol who are on stable doses of statin medications, and to healthy subjects with elevated cholesterol
Conditions Studied
Interventions
- DRUG Placebo
- DRUG LGT209
Study Locations (2)
Florida
- Novartis Investigative Site - Miami Gardens
North Dakota
- Novartis Investigative Site - Fargo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 74 participants |
| Start Date | 2010-12 |
| Est. Completion | 2011-11 |
| Phase | Phase 1 |
What the finished NCT01979601 record still lists
NCT01979601 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 74 participants, a relatively small participant target, below the 816-participant average among 62 other Hypercholesterolemia trials with a reported enrollment target (91% lower).
The record links to 1 condition, with Hypercholesterolemia appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT01979601 reports a single indexed study location in Florida, North Dakota.
Frequently Asked Questions
What is clinical trial NCT01979601 about?
NCT01979601 is a clinical study titled "Safety, Tolerability, PK and PD of LGT209 in Healthy Volunteers and Patients With Hypercholesterolemia". This study is designed to measure the effects of LGT209 when given intravenously to patients with high cholesterol who are on stable doses of statin medications, and to healthy subjects with elevated cholesterol
What is the current status of trial NCT01979601?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 74 participants. The study started on 2010-12. Estimated completion is 2011-11.
What conditions does trial NCT01979601 study?
This clinical trial studies the following conditions: Hypercholesterolemia.
What interventions are being tested in trial NCT01979601?
The interventions under investigation include: Placebo (DRUG), LGT209 (DRUG).
Who is sponsoring clinical trial NCT01979601?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01979601 being conducted?
This trial has 2 study locations across Florida, North Dakota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hypercholesterolemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01979601's enrollment target sits among peer trials
74 45th of 62 higher than 18 of 62 other Hypercholesterolemia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hypercholesterolemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Safety And Tolerability Of Multiple Doses Of PF-04950615 (RN316) In Subjects With Hypercholesterolemia
COMPLETED · Phase 1
-
Study of the Response of Human Small Blood Vessels
COMPLETED · Phase 1
-
A Study of LY3015014 in Healthy Participants With High Cholesterol
COMPLETED · Phase 1
-
Pilot Program to Improve Statin Adherence and Lower Cholesterol in Older Adults
COMPLETED · Phase 1
-
Potential Risk Factors for Stroke
COMPLETED · Phase 1
-
Ascending Multi-dose Study of REGN727(SAR236553) With and Without Concomitant Atorvastatin
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03422731 · 74 participants · Early Phase 1
Multi-modality Imaging and Collection of Biospecimen Samples in Understanding Bone Marrow Changes in Patients With Acute Myeloid Leukemia Undergoing TBI and Chemotherapy
- NCT03804853 · 74 participants · NA
Rehabilitation Following Reverse Total Shoulder Arthroplasty
- NCT04065776 · 74 participants · NA
Evaluation of Hippocampal-Avoidance Using Proton Therapy in Low-Grade Glioma
- NCT04771156 · 74 participants · Phase 4
Ketorolac in Palatoplasty
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia